冠心病患者在药物洗脱支架置入前后热休克蛋白60抗体水平的变化及意义

Changes of Anti-heat shock Protein 60 Level in Patients with Stable Coronary Artery Disease Before and after Drug-eluting Stent Implantation

[目的]比较稳定性冠心病患者热休克蛋白60（HSP60）抗体在药物洗脱支架（DES）置入前后的浓度变化,探讨基线HSP60抗体水平与心血管事件的关系.[方法]入选98例稳定性冠心病,收集临床资料.以酶联免疫吸附法测定冠状动脉介入（PCI）前后血浆HSP60抗体浓度.根据基线HSP60抗体水平分层,随访8个月主要不良心血管事件.[结果]DES置入8个月后随访HSP60抗体浓度明显低于于基线水平（33.65±1.94 vs 39.94±2.73 U/mL,P=0.019）.HSP60高水平组死亡、非致死性冠状动脉综合征、再入院、再次PCI及复合终点与低水平组差异无显著性（P〉0.05）.[结论]稳定性冠心病患者药物洗脱支架置入后HSP60抗体水平显著降低,HSP60水平与短期内主要不良心血管事件无明显相关.

[Objective] To compare the changes of anti-heat shock protein 60 （HSP60） concentration in stable coronary artery disease before and after drug eluting stent（DES） implantation and to explore the relationship between anti-HSP60 baseline level and the cardiovascular events. [Methods] The clinical data of 98 patients with stable coronary artery disease were collected. Enzyme-linked immunosorbent assay（ELISA） was used to determine plasma anti-HSP60 level before and after percutaneous coronary intervention（PCD. According to baseline anti-HSP60 level, patients were stratified. The main adverse cardiovascular events were followed up for 8 months. [Results] The anti-HSP60 level at 8 months after DES implantation was significantly lower than baseline level（33.65 ±1.94 vs 39.94 ± 2.73 U/mL, P = 0.019）. There was no difference in death, non-fetal coronary syndrome, readmission, re PCI and combined endpoints between high anti-HSP60 group and low anti-HSP60 group（ P 〉0.05）. [Conclusion] Anti HSP60 level in stable coronary artery disease after DES implantation decreases significantly. The level of anti-HSP60 has no obvious association with short-term adverse cardiovascular events.